

# TAYSIDE PRESCRIBER

## Tayside DTC Supplement No 67

March 2007

*Produced by NHS Tayside Drug and Therapeutics Committee*

### SMC Advice issued in March 2007

Medicine	Indication	Local recommendation category	Comments and useful links
Alglucosidase alfa (Myozyme <sup>®</sup> )	Pompe disease	Not recommended	<a href="#">SMC advice</a>
Amlodipine/valsartan (Exforge <sup>®</sup> ) – abbreviated submission	Hypertension	Non-formulary	<a href="#">SMC advice</a> <a href="#">SPC link</a>
Buprenorphine/naloxone (Suboxone <sup>®</sup> )	Opioid drug dependence	Pending update of Tayside prescribing protocol for medical treatments of drug misusers	<a href="#">SMC advice</a>
Clostridium botulinum type A toxin (Dysport <sup>®</sup> )	Focal spasticity	Not recommended	<a href="#">SMC advice</a>
Glyceryl trinitrate 0.4% rectal ointment (Rectogesic <sup>®</sup> ) - resubmission	Pain associated with chronic anal fissure	Not recommended	<a href="#">SMC advice</a>
Ivabradine (Procoralan <sup>®</sup> ) - resubmission	Chronic stable angina	Non-formulary	Restricted to angina patients intolerant of beta blockers and rate-limiting calcium channel blockers who remain symptomatic despite nitrates/nicorandil <a href="#">SMC advice</a> <a href="#">SPC link</a>
Lidocaine 5% medicated plaster (Versatis <sup>®</sup> )	Post-herpetic neuralgia	Not recommended	<a href="#">SMC advice</a>
Parathyroid hormone (Preotact <sup>®</sup> )	Severe osteoporosis	HOSPITAL ONLY (Bone clinic)	Alternative to teriparatide <a href="#">SMC advice</a> <a href="#">SPC link</a> <a href="#">Local PTH protocol</a>
Pioglitazone (Actos <sup>®</sup> )	Triple therapy in type 2 diabetes	Formulary (prescribing note)	<a href="#">SMC advice</a> <a href="#">SPC link</a>

### Glitazone update

Local advice for the use of rosiglitazone and pioglitazone has been updated following the issue of new oral hypoglycaemic drug prescribing guidance from the diabetes MCN. This update relates to **type 2 diabetics with BMI of 27 and over**.

- Glitazone monotherapy is recommended in patients in whom metformin is contraindicated.
- Glitazone/metformin dual combination therapy is recommended in patients unable to achieve glycaemic control on monotherapy.
- Sulphonylurea/metformin/glitazone triple therapy is recommended prior to the use of insulin in patients unable to achieve glycaemic control on dual combination therapy.

[Click here](#) for more information

## TAPG Update

	TAPG section	Drug(s)/topic	Changes
6	Endocrine	Rosiglitazone* Pioglitazone*	Incorporation of recent MCN guidance – see above.

\* SMC accepted medicines

## Forthcoming SMC Advice

### **Status of SMC advice in relation to SIGN**

The Chief Medical Officer has advised that where there is disparity between SIGN and SMC advice, SMC advice should normally take precedence.

[Click here](#) for details of the status of the different types of NICE advice in NHS Scotland.

**Contact details:** Local implementation of SMC recommendations is being taken forward by the Tayside Medicines Unit - contact Jan Jones, Principal Pharmacist - Pharmacoeconomics ([janjones@nhs.net](mailto:janjones@nhs.net)) if you have any queries in relation to the introduction of new drugs within NHS Tayside.

This bulletin is based on evidence available to the Tayside Medicines Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website ([www.nhstaysideadtc.scot.nhs.uk](http://www.nhstaysideadtc.scot.nhs.uk)).